{"filing":{"accession_number":"0001193125-26-343408","cik":"0001501796","ticker":"AURA","company_name":"Aura Biosciences, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"aura-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526343408/aura-20260811.htm"},"events":[{"id":26850,"run_id":24421,"accession_number":"0001193125-26-343408","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Aura Biosciences issued a press release announcing its financial results for Q2 2026 (quarter ended June 30, 2026), disclosing a net loss of $45.6 million, cash position of $323.8 million, R\u0026D expenses of $30.7 million, and G\u0026A expenses of $17.3 million, along with business highlights and operational updates.","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28126,"accession_number":"0001193125-26-343408","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing Aura Biosciences' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial metrics including cash position ($323.8M), R\u0026D expenses ($30.7M), G\u0026A expenses ($17.3M), and net loss ($45.6M), along with business highlights and operational updates. This is material to investors as it provides the periodic financial performance and cash runway guidance essential to assessing the company's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28129,"accession_number":"0001193125-26-343408","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"This Item 8.01 disclosure contains multiple material events that do not fit neatly into a single taxonomy category: (1) earnings release (Q2 2026 financial results with net loss of $45.6M); (2) executive appointments (Susan Abu-Absi as COO, Erica Kratz as Chief Regulatory Officer, Julie Person as Chief People Officer); (3) executive departures (Tony Gibney, Conor Kilroy, Mark Plavsic stepping down); and (4) workforce reduction (~20% reduction in force with $2.9–3.2M restructuring charges). The filing's primary focus appears to be a strategic business realignment toward ocular oncology with associated organizational restructuring, but the domain encompasses financial results, leadership changes, and operational restructuring simultaneously, making it difficult to assign a single dominant event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":26851,"run_id":24421,"accession_number":"0001193125-26-343408","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Aura Biosciences announced an organizational realignment involving a workforce reduction of approximately 20%, with estimated restructuring costs of $2.9–$3.2 million primarily for severance benefits and related exit costs, expected to be substantially complete by the end of Q3 2026.","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28127,"accession_number":"0001193125-26-343408","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.05 discloses an organizational realignment involving a workforce reduction of approximately 20%, with estimated restructuring costs of $2.9–$3.2 million, primarily for severance benefits and related exit costs. The filing explicitly states these costs are \"expected to be paid in the third quarter of 2026,\" and the restructuring plan is \"expected to be substantially complete by the end of the third quarter of 2026.\" This is a classic workforce reduction event with quantified exit costs, material to investors assessing the company's operational strategy and cash burn.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28129,"accession_number":"0001193125-26-343408","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"This Item 8.01 disclosure contains multiple material events that do not fit neatly into a single taxonomy category: (1) earnings release (Q2 2026 financial results with net loss of $45.6M); (2) executive appointments (Susan Abu-Absi as COO, Erica Kratz as Chief Regulatory Officer, Julie Person as Chief People Officer); (3) executive departures (Tony Gibney, Conor Kilroy, Mark Plavsic stepping down); and (4) workforce reduction (~20% reduction in force with $2.9–3.2M restructuring charges). The filing's primary focus appears to be a strategic business realignment toward ocular oncology with associated organizational restructuring, but the domain encompasses financial results, leadership changes, and operational restructuring simultaneously, making it difficult to assign a single dominant event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":26852,"run_id":24421,"accession_number":"0001193125-26-343408","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.9,"summary":"Aura Biosciences appointed Susan Abu-Absi as Chief Operating Officer effective August 10, 2026, with compensation terms including $520,000 base salary, 45% bonus target, and approximately 400,000 shares in equity awards (60% options, 40% RSUs). The company also appointed Erica Kratz as Chief Regulatory Officer and Julie Person as Chief People Officer.","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28128,"accession_number":"0001193125-26-343408","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Item 5.02 disclosure centers on the appointment of Susan Abu-Absi as Chief Operating Officer effective August 10, 2026, with detailed compensation terms including $520,000 base salary, 45% bonus target, and approximately 400,000 shares in equity awards (60% options, 40% RSUs). While the section also discloses the departure of Anthony Gibney as Chief Financial and Business Officer and the appointment of Amy Elazzouzi as interim principal financial officer, the primary focus and most substantive disclosure is Abu-Absi's appointment as COO, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28129,"accession_number":"0001193125-26-343408","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"This Item 8.01 disclosure contains multiple material events that do not fit neatly into a single taxonomy category: (1) earnings release (Q2 2026 financial results with net loss of $45.6M); (2) executive appointments (Susan Abu-Absi as COO, Erica Kratz as Chief Regulatory Officer, Julie Person as Chief People Officer); (3) executive departures (Tony Gibney, Conor Kilroy, Mark Plavsic stepping down); and (4) workforce reduction (~20% reduction in force with $2.9–3.2M restructuring charges). The filing's primary focus appears to be a strategic business realignment toward ocular oncology with associated organizational restructuring, but the domain encompasses financial results, leadership changes, and operational restructuring simultaneously, making it difficult to assign a single dominant event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28126,"accession_number":"0001193125-26-343408","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing Aura Biosciences' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 disclosure explicitly states the company \"issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial metrics including cash position ($323.8M), R\u0026D expenses ($30.7M), G\u0026A expenses ($17.3M), and net loss ($45.6M), along with business highlights and operational updates. This is material to investors as it provides the periodic financial performance and cash runway guidance essential to assessing the company's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-08-11"},{"id":28127,"accession_number":"0001193125-26-343408","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.05 discloses an organizational realignment involving a workforce reduction of approximately 20%, with estimated restructuring costs of $2.9–$3.2 million, primarily for severance benefits and related exit costs. The filing explicitly states these costs are \"expected to be paid in the third quarter of 2026,\" and the restructuring plan is \"expected to be substantially complete by the end of the third quarter of 2026.\" This is a classic workforce reduction event with quantified exit costs, material to investors assessing the company's operational strategy and cash burn.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-08-11"},{"id":28128,"accession_number":"0001193125-26-343408","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Item 5.02 disclosure centers on the appointment of Susan Abu-Absi as Chief Operating Officer effective August 10, 2026, with detailed compensation terms including $520,000 base salary, 45% bonus target, and approximately 400,000 shares in equity awards (60% options, 40% RSUs). While the section also discloses the departure of Anthony Gibney as Chief Financial and Business Officer and the appointment of Amy Elazzouzi as interim principal financial officer, the primary focus and most substantive disclosure is Abu-Absi's appointment as COO, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-08-11"},{"id":28129,"accession_number":"0001193125-26-343408","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"This Item 8.01 disclosure contains multiple material events that do not fit neatly into a single taxonomy category: (1) earnings release (Q2 2026 financial results with net loss of $45.6M); (2) executive appointments (Susan Abu-Absi as COO, Erica Kratz as Chief Regulatory Officer, Julie Person as Chief People Officer); (3) executive departures (Tony Gibney, Conor Kilroy, Mark Plavsic stepping down); and (4) workforce reduction (~20% reduction in force with $2.9–3.2M restructuring charges). The filing's primary focus appears to be a strategic business realignment toward ocular oncology with associated organizational restructuring, but the domain encompasses financial results, leadership changes, and operational restructuring simultaneously, making it difficult to assign a single dominant event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:06:55.918362+00:00","company_name":"Aura Biosciences, Inc.","ticker":"AURA","filing_date":"2026-08-11"}]}